The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Including Jazz’s planned acquisition of Actio, nearly two dozen privately held drugmakers have been purchased this year in deals with at least $50 million in guaranteed proceeds.

    Updated Aug. 10, 2026
  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Leo Pharma buys rare skin disease drug in $435M deal

    Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

  • Formation Bio has tapped Biogen and Pfizer vet Mike Ehlers to be its new R&D chief
    Image attribution tooltip
    Permission granted by Image courtesy of Formation Bio
    Image attribution tooltip
    Profile

    Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

    Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca scores in lung cancer; Sandoz inks a China deal

    A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated Aug. 7, 2026
  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    EyePoint plummets on pivotal data for main drug

    Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

  • A financial graph on an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx jumps on Phase 3 data for blockbuster Vyvgart

    The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

  • Left to right: Gregory Oakes, chief executive officer of Slate Medicines, and Neil Buckley, chief operating officer of Slate Medicines.
    Image attribution tooltip
    Permission granted by Slate Medicines
    Image attribution tooltip

    Slate, Fulcrum to combine in reverse merger

    Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

  • A white building entrance sign reads "Bristol Myers Squibb," with a barbed fence behind it surrounded by flowers.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

    The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    At least seven biotechs have announced venture fundings since Monday, representing the busiest calendar week in two months among the investment firms BioPharma Dive tracks.

    Updated Aug. 13, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

    The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

  • Illustration of lung cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Taiho, Cullinan data heats up lung cancer drug battle

    The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

  • A photo depicting a vial of Eli Lilly's obesity drug retatrutide and a syringe.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

    Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    A new BioPharma Dive analysis shows that, in 2026, drugmakers are paying considerably more for rights to China-based medicines than they were last year.

    Updated Aug. 14, 2026
  • A rendering of an adeno-associated virus, colored blue-green, on a black background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    PTC takes a chance on Sangamo’s Fabry disease gene therapy

    Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

  • psychedelic brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Psychedelics developer Definium scores more positive data for LSD pill

    Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

  • An illustration of lymphocytes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Boulevard starts up with $65M to pursue targeted autoimmune drugs

    Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

    Updated Aug. 4, 2026
  • President Trump holding up an executive order on vaccines.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Vaccines

    Trump signs order seeking to upend childhood vaccine schedule

    The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

    FDA
  • A close-up of a child's hands with red, irritated skin on the wrist.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

    Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

  • A person works in Sionna Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Sionna Therapeutics
    Image attribution tooltip

    Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

    Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

  • gene editing crispr cartoon
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Gene editing

    Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

    The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

    Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

  • This image shows a digital illustration of red blood cells flowing through a blood vessel. The red blood cells are shown in a close-up view, and the vessel is shown as a red, translucent tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Vaderis hauls in $152M to test an AKT-targeting drug

    The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.